NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM3308174 Query DataSets for GSM3308174
Status Public on Mar 04, 2019
Title Patient D4
Sample type SRA
 
Source name CDK4/6 inhibitor treated patient biopsy
Organism Homo sapiens
Characteristics sample type: Tissue
cdk4/6 inhibitor phenotype: Sensitive
Treatment protocol All patients were treated with a CDK4/6
Extracted molecule total RNA
Extraction protocol Qiagen's AllPrep DNA/RNA/miRNA Universal
NEBNext® Small RNA Library Prep Set for Illumina, as per manufacturers instructions
 
Library strategy miRNA-Seq
Library source transcriptomic
Library selection size fractionation
Instrument model Illumina NextSeq 500
 
Description RNA derived from CDK4/6 inhibitor treated patient biopsy
Data processing Raw counts were normalised to Counts per million. CPM was used for direct comparisons between patient phenotypes. Genome_build: hg19
 
Submission date Jul 26, 2018
Last update date Mar 04, 2019
Contact name Liam Cornell
E-mail(s) liam_cornell@dfci.harvard.edu
Organization name Dana-Farber Cancer Institute
Street address 450 brookline avenue
City boston
State/province MASSACHUSETTS
ZIP/Postal code 02215
Country USA
 
Platform ID GPL18573
Series (2)
GSE117747 MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance (miRNA-Seq)
GSE117748 MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance
Relations
BioSample SAMN09725044
SRA SRX4474121

Supplementary data files not provided
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap